Nasdaq Turns Positive; Crude Oil Moves Higher
U.S. stocks pared losses midway through trading, with the S&P 500 and Nasdaq Composite turning higher on Tuesday.
Recap: Phathom Pharmaceuticals Q2 Earnings
Phathom Pharmaceuticals (NASDAQ:PHAT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
67 Biggest Movers From Yesterday
Gainers
Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital.
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and Drug Administration approved by May 2021.
FDA Accepts Review Of Phathom Pharmaceuticals’ NDA For Vonoprazan
The Food and Drug Administration (FDA) has accepted for review Phathom Pharmaceuticals’ (NASDAQ: PHAT) New Drug Application (NDA) of its lead drug candidate Vonoprazan for the healing of all grades of erosive esophagitis (EE).
The Daily Biotech Pulse: Third FDA Rejection For Verrica’s Skin Disease Drug, Assembly Bio Terminates Hepatitis B Virus Pact, Consistency Data For Valneva’s Chikungunya Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours.
81 Biggest Movers From Yesterday
Gainers
Eos Energy Enterprises, Inc. (NASDAQ: EOSE) shares gained 41.8% to settle at $1.90 on Tuesday. Eos Energy Enterprises recently reported worse-than-expected Q1 EPS and sales results.
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a measure of innovation in drug research, tapered to merely one for the month.